ProMIS advances PMN310 with FDA Fast Track and $21.6M financing, but cash and dilution risks loom

ProMIS Neurosciences Inc. (PINK: ARFXF) - quick read on what's happening inside the company and what the income statement says.

Snapshot - what's happening now

The company has aggressively stepped up clinical spending to advance its lead program PMN310 (Phase 1b PRECISE‑AD). Management reports positive operational milestones (FDA Fast Track designation for PMN310 and >50% enrollment in the trial as of Aug 13, 2025). At the same time cash burn is high, liquidity was tight at June 30, 2025 and management raised financing in July 2025 to bridge near-term needs.

Key facts and figures (reported)

* Cash (June 30, 2025): $4,510,119
* Short‑term investments: $33,051
* Total assets: $9,509,496
* Total liabilities: $9,892,074
* Shareholders' (deficit) equity: $(382,578)
* Common shares outstanding: 32,689,190
* Weighted‑average shares (basic & diluted): 34,851,203 (six months to June 30, 2025)
* Warrants outstanding (total): 57,141,386
* Options outstanding under plans: 3,760,859
* Total common share equivalents (June 30, 2025): 93,592,496

Income statement highlights - quarterly and six‑month

* Research & development (Q2 2025): $8,749,784 (Q2 2024: $1,625,821)
* General & administrative (Q2 2025): $1,434,877 (Q2 2024: $1,087,885)
* Total operating expenses (Q2 2025): $10,184,661 (up from $2,713,706)
* Loss from operations (Q2 2025): $(10,184,661)
* Net loss (Q2 2025): $(10,117,029) - Net loss per share, basic & diluted: $(0.29)
* Six months ended June 30, 2025 - Net loss: $(17,464,932); net loss per share: $(0.50)

Cash flow and liquidity

* Net cash used in operating activities (six months to June 30, 2025): $(8,781,048)
* Cash at period end: $4.51M (down from $13.29M at Jan 1, 2025)
* Management states the June 30, 2025 cash and the July 2025 financings are still not sufficient to fund operations for at least 12 months from the issuance date - substantial doubt about going concern disclosed.

Financing / subsequent events (material)

* July 2025 receipts (gross): $21.6M from a mix of discounted warrant exercises (~$15.9M), private placements / PIPEs ($2.4M and $3.0M) and a registered direct (~$0.8M). Transaction fees not fully determined.
* ATM program terminated July 21, 2025.
* Numerous new warrants issued in July 2025 with exercise price $1.25 and five‑year terms - potential future dilution if exercised.

Positive aspects (income statement and business)

* Clinical progress: substantial R&D spend is funding PMN310 Phase 1b; FDA granted Fast Track designation - a favorable regulatory development.
* Clear R&D focus: PMN310 makes up the majority of program spend; management is deploying capital toward a prioritized clinical program.
* Successful near‑term financing in July 2025 raised material proceeds (~$21.6M gross) that reduce immediate cash pressure.

Negative aspects (income statement and risks)

* Rapidly increasing cash burn - R&D expense rose to $14.21M for six months (2025) vs $3.75M (2024).
* Working capital and equity position deteriorated: shareholders' deficit of $(382,578) and accumulated deficit $108.15M at June 30, 2025.
* Substantial dilution risk: 57.1M warrants outstanding plus options and new warrants from July financings - large overhang.
* Going concern: management discloses substantial doubt about continuing as a going concern without additional financing.
* Internal control weakness: material weakness identified around fair‑value review of financial instruments (warrant liability) - governance / reporting risk.

What to watch next

* PMN310 interim data milestones (six‑month interim expected Q2 2026; topline Q4 2026) - clinical readouts will drive valuation sentiment.
* Progress on cash runway: actual net cash after July financings, and timing/size of any further equity or collaboration financing.
* Warrant exercises and dilution trajectory - monitor exercised warrants, conversion mechanics and any conditional equity issuances.
* Remediation of the disclosed material weakness in internal controls.

Bottom line: ProMIS is spending heavily to advance a promising lead antibody program (PMN310) and has secured short‑term financing in July 2025, but faces high burn, a weakened balance sheet, material dilution risk and a formal going‑concern disclosure. Clinical progress (Fast Track + ongoing enrollment) is the key value driver - funding and execution determine whether that value can be realized without severe dilution.